<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00873808</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000614118</org_study_id>
    <secondary_id>S0307A</secondary_id>
    <secondary_id>U10CA032102</secondary_id>
    <nct_id>NCT00873808</nct_id>
  </id_info>
  <brief_title>S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307</brief_title>
  <official_title>Long-Term Bone Quality in Women With Breast Cancer (A Companion Study to S0307)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Gathering information over time from imaging and laboratory tests of women&#xD;
      receiving bisphosphonates for breast cancer may help doctors learn more about long-term bone&#xD;
      quality and plan the best treatment. Tetracycline hydrochloride and demeclocycline&#xD;
      hydrochloride can mark the new growth of the bone, so it may be seen better under a&#xD;
      microscope.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying long-term bone quality in women with breast cancer&#xD;
      enrolled on clinical trial SWOG-S0307.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To assess if long-term high-dose bisphosphonates alter bone quality as measured by&#xD;
           change in the histomorphometry of bone biopsies after tetracycline hydrochloride&#xD;
           labeling to calculate eroded and osteoid surfaces, mineralization surface, bone&#xD;
           formation rate, wall width, and activation frequency.&#xD;
&#xD;
        -  To assess if long-term high-dose bisphosphonates alter bone quality as measured by&#xD;
           change in the backscattered electron imaging of bone to measure average mineralization&#xD;
           density as well as distribution of density values.&#xD;
&#xD;
        -  To assess if long-term high-dose bisphosphonates alter bone quality as measured by&#xD;
           change in the micro-computed tomography of bone biopsy specimens to measure bone&#xD;
           structure, including bone volume, connectivity, trabecular width, and cortical width.&#xD;
&#xD;
        -  To assess if long-term high-dose bisphosphonates alter bone quality as measured by&#xD;
           change in the biomechanical testing of bone biopsy samples loaded in compression to&#xD;
           measure stress-strain relationships, including Young's modulus, yield point, ultimate&#xD;
           strain, and work to failure (toughness).&#xD;
&#xD;
        -  To characterize bone using classical, non-invasive techniques (i.e., measurement of bone&#xD;
           mineral density of spine and hip using dual energy x-ray absorptiometry and analysis of&#xD;
           serum biochemical markers of bone formation [i.e., bone specific alkaline phosphatase]&#xD;
           and resorption [i.e., N-telopeptide]) after long-term, high-dose bisphosphonates.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      At baseline (prior to initiating bisphosphonate therapy on SWOG-S0307), patients receive oral&#xD;
      tetracycline hydrochloride twice daily on days 1 and 2 and oral demeclocycline hydrochloride&#xD;
      twice daily on days 11 and 12. Patients undergo a tetracycline hydrochloride-labeled bone&#xD;
      biopsy from the anterior ilium on day 14. At 36 months (for patients who have completed&#xD;
      bisphosphonate therapy) or after 30 months of concurrent bisphosphonate therapy, patients&#xD;
      receive oral demeclocycline twice daily on days 1 and 2 and oral tetracycline hydrochloride&#xD;
      twice daily on days 11 and 12. Patients undergo a demeclocycline hydrochloride-labeled bone&#xD;
      biopsy from the anterior ilium on day 14.&#xD;
&#xD;
      Patients undergo dual energy x-ray absorptiometry measurements of the hip and spine at the&#xD;
      time of biopsy or within the next 10 weeks. Blood samples are collected for analysis of bone&#xD;
      specific alkaline phosphatase and N-telopeptide before and after treatment on the clinical&#xD;
      trial.&#xD;
&#xD;
      After completion of study treatment, patients are followed for up to 10 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of accrual&#xD;
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Change in bone quality after long-term high-dose bisphosphonates as measured by histomorphometry, mineralization density, micro-computed tomography, and biomechanics of bone biopsy samples</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the potency of bisphosphonates as measured by changes in bone quality in each treatment group</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations among measures of bone formation, structure, mineralization, and strength</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clodronate disodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>demeclocycline hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibandronate sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tetracycline hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>dual x-ray absorptiometry</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Concurrently enrolled on clinical trial SWOG-S0307 and receiving bisphosphonates as&#xD;
             adjuvant therapy for primary breast cancer&#xD;
&#xD;
          -  No rickets, osteogenesis imperfecta, osteosclerosis, or osteomalacia&#xD;
&#xD;
          -  No bone fracture since the age of 21 years unless it was caused by trauma&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Weight &lt; 300 lbs&#xD;
&#xD;
          -  No hyperparathyroidism&#xD;
&#xD;
          -  No serious concurrent or prior anorexia nervosa diagnosed by a physician and causing&#xD;
             abnormal menstruation&#xD;
&#xD;
          -  No history of hypersensitivity to tetracycline or demeclocycline&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 10 years since prior prednisone at a dose above 5 mg/day for â‰¥ 3 months&#xD;
&#xD;
          -  No prior prednisone before diagnosis of breast cancer&#xD;
&#xD;
          -  No prior bisphosphonate therapy&#xD;
&#xD;
          -  No concurrent anticonvulsant medications&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn Hershman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Herbert Irving Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Cancer Center at University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 1, 2009</study_first_submitted>
  <study_first_submitted_qc>April 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2009</study_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
    <mesh_term>Ibandronic Acid</mesh_term>
    <mesh_term>Clodronic Acid</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Demeclocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

